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in AMD patients versus € 1,287 in controls. Of the €12,156 per
AMD patient, 9% were AMD drug costs, 14% were direct
vision-related medical costs, 9 % were direct other medical costs,
and 68% were non-medical costs. CONCLUSION: In Germany,
bilateral AMD patients reported substantially worse quality of
life, poorer vision-related functioning, and higher economic
burden compared to controls without AMD. AMD poses signif-
icant emotional and ﬁnancial burdens to the society.
MC6
HOW DO THE SCORES OF GENERIC HRQOL INSTRUMENTS
REFLECT THE DIRECT TTO VALUATIONS OF OWN HEALTH
BY GENERAL POPULATION?
Kotomäki T, Honkalampi T, Sintonen H
University of Helsinki, Helsinki, Finland
OBJECTIVES: To ﬁnd out how the average HRQoL scores 
produced by the generic instruments 15D, HUI3, EQ-5D (with
UK and US TTO valuations), AQoL and SF-6D in different
age/gender groups of the general population reﬂect the direct
TTO valuations of own health in these groups. To be valid for
QALY calculations, the scores should reﬂect a true trade-off
between quality and length of life. At least theoretically, TTO
valuations of own health should do that. METHODS: Popula-
tion survey with a representative sample from 16 age/gender
groups (n = 250 per group, 17–24, 25–34, . . . , 85+ years). The
trade-offs between length and quality of life implicit in the
average scores produced by the instruments in these groups in
population surveys were made explicit. The respondents in each
group chose between the number of years implied by different
instruments that the respondents on average should be willing to
give up for full health or indicated their own preferred number
or unwillingness to trade-off. RESULTS: The average 15D scores
were almost identical with the average TTO valuations up to the
age of 75, but thereafter lower. The HUI3 scores were second
and EQ-5D US third closest, whereas the scores of other instru-
ments were much lower. The SF-6D and AQoL scores were par-
ticularly low in comparison to others in younger age groups (up
to the age of 65), SF-6D and EQ-5D UK scores in older age
groups, and the EQ-5D UK scores especially the oldest age group
(85+). CONCLUSION: To the extent that TTO valuations of
own health are valid, the 15D scores are most valid for QALY
calculations. The scores of other instruments (apart from HUI3
and EQ-5D US) are much lower and the gap tends to widen with
increasing age thus rendering their validity in QALY calculations
questionable.
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OBJECTIVES: The Ankylosing Spondylitis Quality of Life
(ASQoL) questionnaire is a unidimensional, disease-speciﬁc
measure of needs-based QoL developed in the UK and The
Netherlands. This study describes the adaptation of the scale into
several additional country languages. METHODS: The ASQoL
was translated into US-English, Canadian-French and English,
French, German, Italian, Spanish and Swedish by dual-panel
methods. Cognitive debrieﬁng interviews were conducted with
AS patients. Psychometric/scaling properties were assessed using
blinded data from two randomized, double-blind, Phase III
studies of adalimumab. Baseline and Week-2 data assessed 
test-retest reliability. Validity was determined by correlation of
ASQoL with SF-36 and Bath AS Functional Index (BASFI) and
by discriminative ability of ASQoL based on disease severity. Item
response theory (Rasch model) tested the ASQoL’s scaling prop-
erties. RESULTS: Cognitive debrieﬁng showed the new language
versions of ASQoL to be clear, relevant and comprehensive. Clin-
ical study sample sizes varied by country. They were sufﬁcient for
psychometric/scaling assessment in US-English (n = 148; 75%M;
mean age 44.7/SD:12.5) and Canadian-English (n = 66; 77.3%M;
mean age 39.8/SD:10.5), sufﬁcient for psychometric but not
scaling analyses for German (n = 37; 70.3%M; mean age
41.9/SD:11.8) and sufﬁcient for preliminary evidence of these
properties for the remaining languages. Test-retest reliability and
Cronbach’s alpha coefﬁcients were high: US-English (0.85, 0.85),
Canadian-English (0.87, 0.86), and German (0.77, 0.79). Corre-
lations of ASQoL with SF 36 and with BASFI in these three lan-
guages were moderate. US-English, Canadian-English, and
German measures were able to discriminate between patients
based on their perceived disease severity (p < 0.01). Comparable
results were obtained for the additional languages. US-English
and Canadian-English exhibited ﬁt to the Rasch model as indi-
cated by non-signiﬁcant χ2 p-values (US = 0.54, Canadian-English
= 0.68), conﬁrming unidimensionality. CONCLUSIONS: The
ASQoL was successfully translated into all languages and was
subsequently acceptable to local patients. Psychometric proper-
ties are excellent for US-English, Canadian-English, and German
and extremely promising for other languages.
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OBJECTIVES: Smoking cessation gains health and generates
savings in health care costs due to reduced incidence in smoking
related diseases, but these savings maybe outweighed by the
medical spending in life years gained. In a cost-effectiveness
analysis from the health care perspective, not only the interven-
tion costs, but all effects on health care costs should be included,
which is rarely done. The current study evaluated tobacco tax
increases, mass media campaigns, minimal counseling, struc-
tured GP-support, telephone counseling, nicotine replacement
therapy with minimal and intensive counseling, and bupropion
with intensive counseling. METHODS: To estimate costs per
(quality adjusted) life year gained, a dynamic population model
was used to project health gains and effects on health care costs.
Sensitivity analyses were performed for variations in costs,
effects, time horizon, program size and discount rates. The esti-
mates included effects on all health care costs. RESULTS: Tax
increases resulted in costs per QALY around 5000. Costs per
QALY for mass media campaigns were below 10,000 for a broad
range of effects, while for individual cessation support they
varied from about 9000 for GP support to 21,000 for telephone
counseling. Evaluating interventions with the same model
improved comparability. However, comparison of interventions
still proved difﬁcult, because interventions are combined in prac-
tice. With that reservation tax increases provided most value for
money. CONCLUSIONS: Cost-effectiveness rates for most inter-
ventions compared to current practice were quite favourable
even accounting for increased medical costs from longer life
expectancies.
